rss
Br J Ophthalmol 89:1196-1200 doi:10.1136/bjo.2004.064212
  • Clinical science
    • Extended reports

Monovision slows juvenile myopia progression unilaterally

  1. J R Phillips
  1. Correspondence to: Dr J R Phillips Department of Optometry and Vision Science, University of Auckland, Private Bag 92019, Auckland, New Zealand; j.phillipsauckland.ac.nz
  • Accepted 6 February 2005

Abstract

Aim: To evaluate the acceptability, effectivity, and side effects of a monovision spectacle correction designed to reduce accommodation and myopia progression in schoolchildren.

Methods: Dominant eyes of 11 year old children with myopia (−1.00 to −3.00 D mean spherical equivalent) were corrected for distance; fellow eyes were uncorrected or corrected to keep the refractive imbalance ⩽2.00 D. Myopia progression was followed with cycloplegic autorefraction and A-scan ultrasonography measures of vitreous chamber depth (VCD) for up to 30 months. Dynamic retinoscopy was used to assess accommodation while reading.

Results: All children accommodated to read with the distance corrected (dominant) eye. Thus, the near corrected eye experienced myopic defocus at all levels of accommodation. Myopia progression in the near corrected eyes was significantly slower than in the distance corrected eyes (inter-eye difference = 0.36 D/year (95% CI: 0.54 to 0.19, p = 0.0015, n = 13); difference in VCD elongation = 0.13 mm/year (95% CI: 0.18 to 0.08, p = 0.0003, n = 13)). After refitting with conventional spectacles, the resultant anisometropia returned to baseline levels after 9–18 months.

Conclusions: Monovision is not effective in reducing accommodation in juvenile myopia. However, myopia progression was significantly reduced in the near corrected eye, suggesting that sustained myopic defocus slows axial elongation of the human eye.

Footnotes

  • Competing interests: The author has no financial interest in the outcome of this research.

  • Ethics statement: This study was approved by the University of Auckland Human Subjects Ethics Committee, which is accredited by the New Zealand Health Research Council.